
Guidelines for the management of cancer-related hypercalcemia
Hypercalcemia of malignancy (HCM) is the most common metabolic complication observed in cancer patients and is associated with a high degree of morbidity and mortality. It is estimated to affect 2% to 30% of patients and is observed more frequently in patients with breast, lung and kidney cancer, as well as multiple myeloma. The Endocrine […]